Allarity Therapeutics Advances Stenoparib Strategy With Patents and CLIA Lab
Allarity Therapeutics announced that new patents and its CLIA-certified laboratory enhance its DRP companion diagnostic strategy for stenoparib. This development supports patient selection for a potential pivotal trial aiming for FDA approval.